Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disulfiram and Chemotherapy in Pancreas Cancer Patients
NCT02671890Phase 1Terminated
- Sponsor
- Mayo Clinic
- Start
- Feb 2016
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of disulfiram in pancreatic cancer (PC) and solid tumor (2 cohorts), sponsored by Mayo Clinic. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Feb 2016; status: terminated.
02
Drugs
disulfiram
03
Conditions
pancreatic cancer (PC)solid tumor
Beyond the preview
Go deeper on NCT02671890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02671890.